Spondyloarthritides

Best Practice and Research: Clinical Rheumatology

Volumn 25, Issue 6, 2011, Pages 825-842

  Baraliakos, Xenofon ^a   Braun, Juergen ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Ankylosing spondylitis; ASAS classification criteria; Axial spondyloarthropathy; Inflammation; Radiographic progression

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ARTICLE; BACKACHE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ENTERITIS; ENTHESITIS; HUMAN; INFUSION REACTION; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REACTIVE ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; SYMPTOM; TREATMENT OUTCOME; TUBERCULOSIS; WELLBEING;

EID: 84856013195     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2011.11.006     Document Type: Review

References (160)

1. Wellcome Trust Case Control C, Australo-Anglo-American Spondylitis C, P.R. Burton, D.G. Clayton, L.R. Cardon, and N. Craddock Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants Nature Genetics 39 11 2007 1329 1337 (Pubitemid 350041542)
2. M.A. Brown Breakthroughs in genetic studies of ankylosing spondylitis Rheumatology (Oxford) 47 2 2008 132 137 (Pubitemid 351168219)
3. M. Cargill, S.J. Schrodi, M. Chang, V.E. Garcia, R. Brandon, and K.P. Callis A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes American Journal of Human Genetics 80 2 2007 273 290 (Pubitemid 46175676)
4. J. Braun, M. Bollow, G. Remlinger, U. Eggens, M. Rudwaleit, and A. Distler Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors Arthritis and Rheumatism 41 1 1998 58 67 (Pubitemid 28041923)
5. J. Brandt, M. Bollow, J. Haberle, M. Rudwaleit, U. Eggens, and A. Distler Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy Rheumatology (Oxford) 38 9 1999 831 836 (Pubitemid 29507364)
6. J.T. Gran, G. Husby, and M. Hordvik Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway Annals of the Rheumatic Diseases 44 6 1985 359 367 (Pubitemid 15053515)
7. A. Saraux, C. Guedes, J. Allain, V. Devauchelle, I. Valls, and A. Lamour Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest Journal of Rheumatology 26 12 1999 2622 2627
8. Braun Jr., and J. Sieper Ankylosing spondylitis Lancet 369 9570 2007 1379 1390 (Pubitemid 46590387)
9. M. Rudwaleit, H. Haibel, X. Baraliakos, J. Listing, E. Marker-Hermann, and H. Zeidler The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort Arthritis and Rheumatism 60 3 2009 717 727
10. A. Zink, J. Braun, J. Listing, and J. Wollenhaupt Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers Journal of Rheumatology 27 3 2000 613 622 (Pubitemid 30151336)
11. M.M. Ward Health-related quality of life in ankylosing spondylitis: a survey of 175 patients Arthritis Care and Research 12 4 1999 247 255 (Pubitemid 29508656)
12. A. Zink, J. Listing, C. Klindworth, and H. Zeidler The national database of the German Collaborative arthritis centres: I. Structure, aims, and patients Annals of the Rheumatic Diseases 60 3 2001 199 206 (Pubitemid 32260599)
13. A. Boonen, A. Chorus, H. Miedema, D. van der Heijde, H. van der Tempel, and S. van der Linden Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients Annals of the Rheumatic Diseases 60 4 2001 353 358 (Pubitemid 32242748)
14. A.M. Chorus, A. Boonen, H.S. Miedema, and S. van der Linden Employment perspectives of patients with ankylosing spondylitis Annals of the Rheumatic Diseases 61 8 2002 693 699 (Pubitemid 34787706)
15. A. Boonen, D. van der Heijde, R. Landewe, A. Spoorenberg, H. Schouten, and M. Rutten-van Molken Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries Annals of the Rheumatic Diseases 61 5 2002 429 437 (Pubitemid 34496822)
16. A. Boonen, D. van der Heijde, R. Landewe, F. Guillemin, A. Spoorenberg, and H. Schouten Costs of ankylosing spondylitis in three European countries: the patient's perspective Annals of the Rheumatic Diseases 62 8 2003 741 747 (Pubitemid 36886408)
17. M.M. Ward Functional disability predicts total costs in patients with ankylosing spondylitis Arthritis and Rheumatism 46 1 2002 223 231 (Pubitemid 34121668)
18. J. Listing, J. Brandt, M. Rudwaleit, A. Zink, J. Sieper, and J. Braun Impact of anti-tumour necrosis factor {alpha} treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis Annals of the Rheumatic Diseases 63 12 2004 1670 1672 (Pubitemid 39573701)
19. M. Leirisalo-Repo Prognosis, course of disease, and treatment of the spondyloarthropathies Rheumatic Disease Clinics of North America 24 4 1998 737 751 (Pubitemid 28524021)
20. B. Amor, M. Dougados, and M.A. Khan Management of refractory ankylosing spondylitis and related spondyloarthropathies Annals of the Rheumatic Diseases 21 1 1995 117 128
21. J. Sieper, T. Klopsch, M. Richter, A. Kapelle, M. Rudwaleit, and S. Schwank Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study Annals of the Rheumatic Diseases 67 3 2008 323 329 (Pubitemid 351281265)
22. X. Baraliakos, J. Listing, C. Fritz, H. Haibel, R. Alten, and G.R. Burmester Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome Rheumatology (Oxford) 2011
23. M.M. Ward Predictors of the progression of functional disability in patients with ankylosing spondylitis Journal of Rheumatology 29 7 2002 1420 1425 (Pubitemid 34755608)
24. A. van Tubergen, R. Landewe, D. van der Heijde, A. Hidding, N. Wolter, and M. Asscher Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial Arthritis and Rheumatism 45 5 2001 430 438 (Pubitemid 32979848)
25. J. Braun, and J. Sieper Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches Arthritis Research 4 5 2002 307 321 (Pubitemid 34947145)
26. I.H. Song, F. Heldmann, M. Rudwaleit, J. Listing, H. Appel, and M. Bogdan Major clinical response of rituximab in active TNF-blocker naive patients with ankylosing spondylitis but not in TNF-blocker-failure patients - an open label clinical trial Annals of the Rheumatic Diseases 68 Suppl. 3 2009 74
27. G. Nocturne, M. Dougados, A. Constantin, C. Richez, J. Sellam, and A.M. Simon Lack of efficacy of rituximab in spondylarthropathies: data of 8 patients prospectively followed in the French AIR Annals of the Rheumatic Diseases 68 Suppl3 2009 626 auto-immunity and rituximab") registry
28. B. Berner, J. Schedel, I. Guenaydin, M. Schmalzing, L. Kanz, and I. Koetter Abatacept for therapy of spondyloarthritis due to therapy failure or contraindications of TNF-alpha antagonists Annals of the Rheumatic Diseases 68 Suppl3 2009 623
29. H. Haibel, M. Rudwaleit, J. Listing, and J. Sieper Open label trial of anakinra in active ankylosing spondylitis over 24 weeks Annals of the Rheumatic Diseases 64 2 2005 296 298 (Pubitemid 40193630)
30. A.N. Bennett, A.L. Tan, L.C. Coates, P. Emery, H. Marzo-Ortega, and D. McGonagle Sustained response to anakinra in ankylosing spondylitis Rheumatology (Oxford) 47 2 2008 223 224 (Pubitemid 351168239)
31. S.H. Laval, A. Timms, S. Edwards, L. Bradbury, S. Brophy, and A. Milicic Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci American Journal of Human Genetics 68 4 2001 918 926 (Pubitemid 32289738)
32. M.A. Brown, S.H. Laval, S. Brophy, and A. Calin Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis Annals of the Rheumatic Diseases 59 11 2000 883 886
33. L. Schlosstein, P.I. Terasaki, R. Bluestone, and C.M. Pearson High association of an HL-A antigen, W27, with ankylosing spondylitis New England Journal of Medicine 5 1973 288 704-6
34. D. Laukens, M. Georges, C. Libioulle, C. Sandor, M. Mni, and B. Vander Cruyssen Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis PLoS One 5 11 2010 e13795
35. J. Braun, M. Bollow, L. Neure, E. Seipelt, F. Seyrekbasan, and H. Herbst Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis Arthritis and Rheumatism 38 4 1995 499 505
36. M. Dougados Diagnostic features of ankylosing spondylitis British Journal of Rheumatology 34 4 1995 301 303
37. E. Feldtkeller [Age at disease onset and delayed diagnosis of spondyloarthropathies] Z Rheumatology 58 1 1999 21 30 (Pubitemid 29128474)
38. M. Rudwaleit, M.A. Khan, and J. Sieper The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis and Rheumatism 52 4 2005 1000 1008 (Pubitemid 40530105)
39. W. Mau, H. Zeidler, R. Mau, A. Majewski, J. Freyschmidt, and W. Stangel Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup HLA-B27 and clinical aspects of ankylosing spondylitis: results of prospective studies Journal of Rheumatology 15 7 1988 1109 1114
40. D. Poddubnyy, M. Rudwaleit, H. Haibel, J. Listing, E. Marker-Hermann, and H. Zeidler Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis Annals of the Rheumatic Diseases 70 8 2011 1369 1374
41. A. Braun, E. Saracbasi, J. Grifka, J. Schnitker, and J. Braun Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? Annals of the Rheumatic Diseases 2011
42. M. Rudwaleit, R. Landewe, D. van der Heijde, J. Listing, J. Brandt, and J. Braun The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal Annals of the Rheumatic Diseases 68 6 2009 770 776
43. M. Rudwaleit, D. van der Heijde, R. Landewe, J. Listing, N. Akkoc, and J. Brandt The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection Annals of the Rheumatic Diseases 68 6 2009 777 783
44. M. Rudwaleit, D. van der Heijde, M.A. Khan, J. Braun, and J. Sieper How to diagnose axial spondyloarthritis early Annals of the Rheumatic Diseases 63 5 2004 535 543 (Pubitemid 38530197)
45. A. Calin, J. Porta, J.F. Fries, and D.J. Schurman Clinical history as a screening test for ankylosing spondylitis Jama 237 24 1977 2613 2614 (Pubitemid 8104225)
46. M. Rudwaleit, A. Metter, J. Listing, J. Sieper, and J. Braun Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria Arthritis and Rheumatism 54 2 2006 569 578 (Pubitemid 43228633)
47. J. Sieper, D. van der Heijde, R. Landewe, J. Brandt, R. Burgos-Vagas, and E. Collantes-Estevez New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS) Annals of the Rheumatic Diseases 68 6 2009 784 788
48. J. Sieper, M. Rudwaleit, X. Baraliakos, J. Brandt, J. Braun, and R. Burgos-Vargas The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis Annals of the Rheumatic Diseases 68 Suppl. 2 2009 ii1-44
49. S. van der Linden, H.A. Valkenburg, and A. Cats Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Arthritis and Rheumatism 27 4 1984 361 368 (Pubitemid 14134775)
50. I. Olivieri, S. D'Angelo, C. Palazzi, A. Padula, R. Mader, and M.A. Khan Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis Current Rheumatology Reports 11 5 2009 321 328
51. X. Baraliakos, J. Listing, M. Rudwaleit, H. Haibel, J. Brandt, and J. Sieper Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes Annals of the Rheumatic Diseases 66 7 2007 910 915 (Pubitemid 46999792)
52. E. Feldtkeller, J. Bruckel, and M.A. Khan Scientific contributions of ankylosing spondylitis patient advocacy groups Current Opinion in Rheumatology 12 4 2000 239 247 (Pubitemid 30439674)
53. J. Braun, M. Bollow, U. Eggens, H. Konig, A. Distler, and J. Sieper Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients Arthritis and Rheumatism 37 7 1994 1039 1045 (Pubitemid 24222095)
54. D.F. Battafarano, S.G. West, K.M. Rak, E.J. Fortenbery, and A.E. Chantelois Comparison of bone scan, computed tomography, and magnetic resonance imaging in the diagnosis of active sacroiliitis Seminar Arthritis and Rheumatism 23 3 1993 161 176 (Pubitemid 24010698)
55. M. Rudwaleit, A.G. Jurik, K.G. Hermann, R. Landewe, D. van der Heijde, and X. Baraliakos Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group Annals of the Rheumatic Diseases 68 10 2009 1520 1527
56. K.G. Hermann, X. Baraliakos, D. van der Heijde, A.G. Jurik, R. Landewe, and H. Marzo-Ortega Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial SpA Annals of the Rheumatic Diseases 69 Suppl. 3 2010 104
57. A.G. Bochkova, A.V. Levshakova, N.V. Bunchuk, and J. Braun Spinal inflammation lesions as detected by magnetic resonance imaging in patients with early ankylosing spondylitis are more often observed in posterior structures of the spine Rheumatology (Oxford) 49 4 2010 749 755
58. J. Braun, X. Baraliakos, W. Golder, K.G. Hermann, J. Listing, and J. Brandt Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems Annals of the Rheumatic Diseases 63 9 2004 1046 1055 (Pubitemid 39120353)
59. B.R. Hawkins, R.L. Dawkins, F.T. Christiansen, and P.J. Zilko Use of the B27 test in the diagnosis of ankylosing spondylitis: a statistical evaluation Arthritis and Rheumatism 24 5 1981 743 746 (Pubitemid 11099296)
60. M.A. Khan Clinical application of the HLA-B27 test in rheumatic diseases. A current perspective Archives of Internal Medicine 140 2 1980 177 180 (Pubitemid 10115908)
61. H.Y. Chung, P. Machado, D. van der Heijde, M.A. D'Agostino, and M. Dougados HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis Annals of the Rheumatic Diseases 2011
62. M. Dougados, S. van der Linden, R. Juhlin, B. Huitfeldt, B. Amor, and A. Calin The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy Arthritis and Rheumatism 34 10 1991 1218 1227
63. M.A. Khan, and M.K. Khan Diagnostic value of HLA-B27 testing ankylosing spondylitis and Reiter's syndrome Annals of Internal Medicine 96 1 1982 70 76 (Pubitemid 12205525)
64. M.A. Khan HLA-B27 polymorphism and association with disease Journal of Rheumatology 27 5 2000 1110 1114
65. J. Zochling, D. van der Heijde, R. Burgos-Vargas, E. Collantes, J.C. Davis Jr., and B. Dijkmans ASAS/EULAR recommendations for the management of ankylosing spondylitis Annals of the Rheumatic Diseases 65 4 2006 442 452
66. J. Braun, R. van den Berg, X. Baraliakos, H. Boehm, R. Burgos-Vargas, and E. Collantes-Estevez 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Annals of the Rheumatic Diseases 70 6 2011 896 904
67. J.M. Berthelot, L. Tortellier, D. Lavy-Bregeon, B. Le Goff, and Y. Maugars High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies? Jt Bone Spine 75 2 2008 167 171
68. D. van der Heijde, J. Sieper, W.P. Maksymowych, M. Dougados, R. Burgos-Vargas, and R. Landewe 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis Annals of the Rheumatic Diseases 70 6 2011 905 908
69. I.H. Song, M. Rudwaleit, J. Listing, and J. Sieper Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations Annals of the Rheumatic Diseases 68 11 2009 1701 1707
70. P. Machado, R. Landewe, E. Lie, T.K. Kvien, J. Braun, and D. Baker Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores Annals of the Rheumatic Diseases 70 1 2011 47 53
71. D. van der Heijde, E. Lie, T.K. Kvien, J. Sieper, F. Van den Bosch, and J. Listing ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis Annals of the Rheumatic Diseases 68 12 2009 1811 1818
72. W.P. Maksymowych, R. Richardson, C. Mallon, D. van der Heijde, and A. Boonen Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis Arthritis and Rheumatism 57 1 2007 133 139
73. X. Baraliakos, J. Listing, A. von der Recke, and J. Braun Radiographic progression in ankylosing spondylitis (AS) - the natural course. A retrospective cohort study Am Coll Rheumatol American College of Rheumatology, Annual Scientific meeting, Oral presentation, November 2007
74. J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, and W. Golder Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 9313 2002 1187 1193 (Pubitemid 34304258)
75. J. Brandt, A. Khariouzov, J. Listing, H. Haibel, H. Sorensen, and L. Grassnickel Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Arthritis and Rheumatism 48 6 2003 1667 1675 (Pubitemid 36682375)
76. D. van der Heijde, A. Kivitz, M.H. Schiff, J. Sieper, B.A. Dijkmans, and J. Braun Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 54 7 2006 2136 2146 (Pubitemid 44051069)
77. J. Braun, X. Baraliakos, J. Listing, C. Fritz, R. Alten, and G. Burmester Persistent clinical efficacy and safety of anti-tumour necrosis factor {alpha} therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response Annals of the Rheumatic Diseases 67 3 2008 340 345 (Pubitemid 351281268)
78. X. Baraliakos, J. Brandt, J. Listing, H. Haibel, H. Sorensen, and M. Rudwaleit Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data Arthritis and Rheumatism 53 6 2005 856 863 (Pubitemid 41811126)
79. X. Baraliakos, J. Listing, C. Fritz, R. Alten, G. Burmester, and A. Krause Persistent clinical efficacy and safety of infliximab in patients with ankylosing spondylitis over 7 years - evidence for different response to anti-TNFa therapy Annals of the Rheumatic Diseases 67 Supp II 2008 375
80. X. Baraliakos, J. Listing, C. Fritz, H. Haibel, I.H. Song, and F. Heldmann Persistent clinical response in patients with ankylosing spondylitis after 5 years of treatment with etanercept Annals of the Rheumatic Diseases 67 Suppl. II 2008 376
81. U. Kiltz, X. Baraliakos, P. Karakostas, M. Igelmann, L. Kalthoff, and D. Krause How much inflammation do patients with axial spondyloarthritis have who report low levels of disease activity? - a prospective cohort study Annals of the Rheumatic Diseases 2011
82. X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, and J. Sieper Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-{alpha} antibody infliximab Rheumatology (Oxford) 46 9 2007 1450 1453 (Pubitemid 47317093)
83. X. Baraliakos, J. Listing, M. Rudwaleit, J. Brandt, H. Zeidler, and J. Sieper Less radiographic progression in patients with active ankylosing spondylitis after 2 Years of anti-tnf therapy Annual Meeting of the American College of Rheumatology, San Antonio, TX, Nov. 12-17, [abstract] 2005
84. D. van der Heijde, R. Landewe, S. Einstein, P. Ory, D. Vosse, and L. Ni Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept Arthritis and Rheumatism 58 5 2008 1324 1331 (Pubitemid 351705922)
85. X. Baraliakos, J. Davis, W. Tsuji, and J. Braun Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept Arthritis and Rheumatism 52 4 2005 1216 1223 (Pubitemid 40530129)
86. J. Sieper, X. Baraliakos, J. Listing, J. Brandt, H. Haibel, and M. Rudwaleit Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab Rheumatology (Oxford) 44 12 2005 1525 1530 (Pubitemid 41742469)
87. A. Hidding, S. van der Linden, and L. de Witte Therapeutic effects of individual physical therapy in ankylosing spondylitis related to duration of disease Clinical Rheumatology 12 3 1993 334 340 (Pubitemid 23306867)
88. A. Hidding, S. van der Linden, M. Boers, X. Gielen, L. de Witte, and A. Kester Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial Arthritis Care and Research 6 3 1993 117 125 (Pubitemid 23268260)
89. A. Hidding, S. van der Linden, X. Gielen, L. de Witte, B. Dijkmans, and D. Moolenburgh Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial Arthritis Care and Research 7 2 1994 90 96 (Pubitemid 24181338)
90. G. Kraag, B. Stokes, J. Groh, A. Helewa, and C. Goldsmith The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis-a randomized controlled trial Journal of Rheumatology 17 2 1990 228 233 (Pubitemid 20108228)
91. A. Wanders, D.V. Heijde, R. Landewe, J.M. Behier, A. Calin, and I. Olivieri Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial Arthritis and Rheumatism 52 6 2005 1756 1765 (Pubitemid 40852884)
92. H. Haibel, J. Braun, and W.P. Maksymowych Bisphosphonates-targeting bone in the treatment of spondyloarthritis Clinical And Experimental Rheumatology 20 6 Suppl. 28 2002 S162 S166
93. B. Muche, M. Bollow, R.J. Francois, J. Sieper, B. Hamm, and J. Braun Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging Arthritis and Rheumatism 48 5 2003 1374 1384 (Pubitemid 36554536)
94. J. Braun, and X. Baraliakos Treatment of ankylosing spondylitis and other spondyloarthritides Current Opinion in Rheumatology 21 4 2009 324 334
95. M. Breban, P. Ravaud, P. Claudepierre, G. Baron, Y.D. Henry, and C. Hudry Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment Arthritis and Rheumatism 58 1 2008 88 97
96. X. Baraliakos, J. Listing, M. Rudwaleit, J. Sieper, and J. Braun The relationship between inflammation and new bone formation in patients with ankylosing spondylitis Arthritis Research and Therapy 10 5 2008 R104
97. J. Brandt, H. Haibel, D. Cornely, W. Golder, J. Gonzalez, and J. Reddig Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab Arthritis and Rheumatism 43 6 2000 1346 1352 (Pubitemid 30416320)
98. E. Kruithof, F. Van den Bosch, D. Baeten, A. Herssens, F. De Keyser, and H. Mielants Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up Annals of the Rheumatic Diseases 61 3 2002 207 212 (Pubitemid 34177749)
99. M. Stone, D. Salonen, M. Lax, U. Payne, V. Lapp, and R. Inman Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis Journal of Rheumatology 28 7 2001 1605 1614 (Pubitemid 32660635)
100. W.P. Maksymowych, G.S. Jhangri, R.G. Lambert, C. Mallon, H. Buenviaje, and E. Pedrycz Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety Journal of Rheumatology 29 5 2002 959 965 (Pubitemid 34493501)
101. E. Collantes-Estevez, M.C. Munoz-Villanueva, J.D. Canete-Crespillo, R. Sanmarti-Sala, J. Gratacos-Masmitja, and P. Zarco-Montejo Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study Annals of the Rheumatic Diseases 62 12 2003 1239 1240 (Pubitemid 37500638)
102. J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, and G. Burmester Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Arthritis and Rheumatism 48 8 2003 2224 2233 (Pubitemid 36959203)
103. T.I. Temekonidis, Y. Alamanos, S.N. Nikas, D.V. Bougias, A.N. Georgiadis, and P.V. Voulgari Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study Annals of the Rheumatic Diseases 62 12 2003 1218 1220 (Pubitemid 37500631)
104. J. Braun, A. Deodhar, B. Dijkmans, P. Geusens, J. Sieper, and P. Williamson Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period Arthritis and Rheumatism 59 9 2008 1270 1278
105. M. Breban, E. Vignon, P. Claudepierre, V. Devauchelle, D. Wendling, and E. Lespessailles Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study Rheumatology (Oxford) 41 11 2002 1280 1285 (Pubitemid 35363803)
106. D. van der Heijde, B. Dijkmans, P. Geusens, J. Sieper, K. DeWoody, and P. Williamson Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo controlled trial (ASSERT) Arthritis and Rheumatism 52 2 2005 582 591 (Pubitemid 40216323)
107. J. Braun, J. Sieper, P. Geusens, B. Dijkmans, J. Han, and W. Xu Efficacy and Safety of infliximab in patients with ankylosing spondylits: 102 week results of the ASSERT trial Annals of the Rheumatic Diseases 65 Suppl. II 2006 87
108. R.N. Jois, J. Leeder, A. Gibb, K. Gaffney, A. Macgregor, and M. Somerville Low-dose infliximab treatment for ankylosing spondylitis-clinically- and cost-effective Rheumatology (Oxford) 45 12 2006 1566 1569 (Pubitemid 44817066)
109. P. Sidiropoulos, H.D. Kritikos, P. Siakka, M. Mamoulaki, H. Kouroumali, and K. Voudouris Low dose of infliximab is inadequate in most patients with spondylarthropathies Clinical Research in Rheumatology 23 4 2005 513 516 (Pubitemid 41447623)
110. H. Marzo-Ortega, D. McGonagle, P. O'Connor, and P. Emery Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study Arthritis and Rheumatism 44 9 2001 2112 2117 (Pubitemid 33644055)
111. J.D. Gorman, K.E. Sack, and J.C. Davis Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha New England Journal of Medicine 346 18 2002 1349 1356 (Pubitemid 34754607)
112. J.C. Davis Jr., D. Van Der Heijde, J. Braun, M. Dougados, J. Cush, and D.O. Clegg Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis and Rheumatism 48 11 2003 3230 3236 (Pubitemid 37409337)
113. J. Davis Jr., A. Webb, S. Lund, and K. Sack Results from an open-label extension study of etanercept in ankylosing spondylitis Arthritis and Rheumatism 51 2 2004 302 304 (Pubitemid 38468720)
114. J. Brandt, J. Listing, H. Haibel, H. Sörensen, A. Schwebig, and M. Rudwaleit Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis Rheumatology (Oxford), 44 3 2005 342 348 (Pubitemid 40361291)
115. M. Rudwaleit, X. Baraliakos, J. Brandt, J. Sieper, and J. Braun Magnetic resonance imaging (MRI) of the spine and the sacroiliac joints (SIJ) in ankylosing spondylitis (AS) before and during therapy with the anti-TNF agent etanercept Arthritis and Rheumatism 50 9 Suppl. 2004 S612
116. D. van der Heijde, M.H. Schiff, J. Sieper, A.J. Kivitz, R.L. Wong, and H. Kupper Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial Annals of the Rheumatic Diseases 68 6 2009 922 929
117. M. Rudwaleit, P. Claudepierre, P. Wordsworth, E.L. Cortina, J. Sieper, and M. Kron Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis Journal of Rheumatology 36 4 2009 801 808
118. R.D. Inman, J.C. Davis Jr., D. Heijde, L. Diekman, J. Sieper, and S.I. Kim Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial Arthritis and Rheumatism 58 11 2008 3402 3412
119. C. Antoni, and J. Braun Side effects of anti-TNF therapy: current knowledge Clinical and Experimental Rheumatology 20 6 Suppl. 28 2002 S152 S157
120. T. Ellerin, R.H. Rubin, and M.E. Weinblatt Infections and anti-tumor necrosis factor alpha therapy Arthritis and Rheumatism 48 11 2003 3013 3022 (Pubitemid 37409310)
121. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent New England Journal of Medicine 345 15 2001 1098 1104
122. J.J. Gomez-Reino, L. Carmona, V.R. Valverde, E.M. Mola, and M.D. Montero Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report Arthritis and Rheumatism 48 8 2003 2122 2127 (Pubitemid 36959191)
123. D. Baeten, E. Kruithof, F. Van den Bosch, N. Van den Bossche, A. Herssens, and H. Mielants Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Annals of the Rheumatic Diseases 62 9 2003 829 834 (Pubitemid 37026492)
124. J.F. Colombel, E.V. Loftus Jr., W.J. Tremaine, L.J. Egan, W.S. Harmsen, and C.D. Schleck The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients Gastroenterology 126 1 2004 19 31 (Pubitemid 38040720)
125. A. Fouque-Aubert, L. Jette-Paulin, C. Combescure, A. Basch, J. Tebib, and L. Gossec Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials Annals of the Rheumatic Diseases 69 10 2010 1756 1761
126. B. Dijkmans, P. Emery, M. Hakala, M. Leirisalo-Repo, E.M. Mola, and L. Paolozzi Etanercept in the longterm treatment of patients with ankylosing spondylitis Journal of Rheumatology 36 6 2009 1256 1264
127. M.K. de Vries, I.E. van der Horst-Bruinsma, M.T. Nurmohamed, L.A. Aarden,
128. C.L. Wagner, A. Schantz, E. Barnathan, A. Olson, M.A. Mascelli, and J. Ford Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade Developmental Biology (Basel) 112 2003 37 53
129. X. Baraliakos, J. Listing, J. Brandt, A. Zink, R. Alten, and G. Burmester Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Arthritis Research and Therapy 7 3 2005 R439 R444
130. M.K. de Vries, G.J. Wolbink, S.O. Stapel, E.R. de Groot, B.A. Dijkmans, and L.A. Aarden Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation Annals of the Rheumatic Diseases 66 1 2007 133 134 (Pubitemid 46044875)
131. M.K. de Vries, E. Brouwer, I.E. van der Horst-Bruinsma, A. Spoorenberg, J.C. van Denderen, and A. Jamnitski Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation Annals of the Rheumatic Diseases 68 11 2009 1787 1788
132. P.J. Charles, R.J. Smeenk, J. De Jong, M. Feldmann, and R.N. Maini Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials Arthritis and Rheumatism 43 11 2000 2383 2390
133. L. De Rycke, E. Kruithof, N. Van Damme, I.E. Hoffman, N. Van den Bossche, and F. Van den Bosch Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy Arthritis and Rheumatism 48 4 2003 1015 1023 (Pubitemid 36418243)
134. F. Bobbio-Pallavicini, C. Alpini, R. Caporali, S. Avalle, S. Bugatti, and C. Montecucco Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment Arthritis Research and Therapy 6 3 2004 R264 R272
135. J. Braun, and J. Sieper Biological therapies in the spondyloarthritides- the current state Rheumatology (Oxford) 43 9 2004 1072 1084 Epub 2004 Jun 8 (Pubitemid 39232810)
136. K.E. Hansen, J.P. Hildebrand, M.C. Genovese, J.J. Cush, S. Patel, and D.A. Cooley The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis Journal of Rheumatology 31 6 2004 1098 1102 (Pubitemid 38715884)
137. R. van Vollenhoven, A. Harju, S. Brannemark, and L. Klareskog Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense Annals of the Rheumatic Diseases 62 12 2003 1195 1198 (Pubitemid 37500626)
138. J.D. Cohen, R. Ferreira, and C. Jorgensen Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab Journal of Rheumatology 38 7 2011 1527
139. J.C. Henes, M. Horger, I. Guenaydin, L. Kanz, and I. Koetter Mixed response to tocilizumab for ankylosing spondylitis Annals of the Rheumatic Diseases 69 12 2010 2217 2218
140. I.H. Song, F. Heldmann, M. Rudwaleit, J. Listing, H. Appel, and J. Braun Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial Arthritis and Rheumatism 62 5 2010 1290 1297
141. I.H. Song, F. Heldmann, M. Rudwaleit, H. Haibel, A. Weiss, and J. Braun Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study Annals of the Rheumatic Diseases 70 6 2011 1108 1110
142. H. Haibel, M. Rudwaleit, J. Listing, F. Heldmann, R.L. Wong, and H. Kupper Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two Arthritis and Rheumatism 58 7 2008 1981 1991 (Pubitemid 351988090)
143. N. Barkham, H.I. Keen, L.C. Coates, P. O'Connor, E. Hensor, and A.D. Fraser Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis Arthritis and Rheumatism 60 4 2009 946 954
144. J. Braun, J. Zochling, X. Baraliakos, R. Alten, G. Burmester, and K. Grasedyck Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial Annals of the Rheumatic Diseases 65 9 2006 1147 1153 (Pubitemid 44277387)
145. P. Emery, F.C. Breedveld, S. Hall, P. Durez, D.J. Chang, and D. Robertson Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial Lancet 372 9636 2008 375 382
146. M. Rudwaleit, J. Listing, J. Brandt, J. Braun, and J. Sieper Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis Annals of the Rheumatic Diseases 63 6 2004 665 670 (Pubitemid 38658395)
147. N. Vastesaeger, D. van der Heijde, R.D. Inman, Y. Wang, A. Deodhar, and B. Hsu Predicting the outcome of ankylosing spondylitis therapy Annals of the Rheumatic Diseases 70 6 2011 973 981
148. N. Yeilding, P. Szapary, C. Brodmerkel, J. Benson, M. Plotnick, and H. Zhou Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives Annals of the New York Academy of Sciences 1222 2011 30 39
149. D. Baeten, J. Sieper, P. Emery, J. Braun, D. van der Heijde, and I. McInnes The anti-IL17a monoclonal antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylonsing spondylitis Annals of the Rheumatic Diseases 70 Suppl3 2011 127
150. X. Baraliakos, J. Listing, M. Rudwaleit, J. Brandt, J. Sieper, and J. Braun Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab Annals of the Rheumatic Diseases 64 10 2005 1462 1466 (Pubitemid 41623858)
151. D. van der Heijde, R. Landewe, X. Baraliakos, H. Houben, A. van Tubergen, and P. Williamson Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis Arthritis and Rheumatism 58 10 2008 3063 3070
152. D. van der Heijde, D. Salonen, B.N. Weissman, R. Landewe, W.P. Maksymowych, and H. Kupper Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years Arthritis Research and Therapy 11 4 2009 R127
153. W.P. Maksymowych, P. Chiowchanwisawakit, T. Clare, S.J. Pedersen, M. Ostergaard, and R.G. Lambert Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation Arthritis and Rheumatism 60 1 2009 93 102
154. X. Baraliakos, H. Haibel, J. Listing, J. Sieper, and J. Braun Radiographic progression in ankylosing spondylitis - results after up to 8 years of anti-TNF treatment Annals of the Rheumatic Diseases 70 Suppl. 3 2011 344
155. A. Wanders, R. Landewe, A. Spoorenberg, K. de Vlam, H. Mielants, and M. Dougados Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order Annals of the Rheumatic Diseases 63 12 2004 1601 1604 (Pubitemid 39573688)
156. A.J. Wanders, R.B. Landewe, A. Spoorenberg, M. Dougados, S. van der Linden, and H. Mielants What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter Arthritis and Rheumatism 50 8 2004 2622 2632 (Pubitemid 39062724)
157. D. Van der Heide, R. Landewe, A. Deodhar, D. Baker, J. Han, and W. Xu Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab Annals of the Rheumatic Diseases 66 Suppl. II 2007 85
158. D. van der Heijde, R. Landewe, P. Ory, D. Vosse, L. Zhou, and W. Tsuji Two-year etanercept therapy does not inhibit radiographic progession in patients with ankylosing spondylitis Annals of the Rheumatic Diseases 65 Suppl. II 2006 81
159. X. Baraliakos, J. Listing, A. von der Recke, and J. Braun The natural course of radiographic progression in ankylosing spondylitis-evidence for major individual variations in a large proportion of patients Journal of Rheumatology 36 5 2009 997 1002
160. X. Baraliakos, J. Listing, M. Rudwaleit, J. Sieper, and J. Braun Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change Arthritis and Rheumatism 61 6 2009 764 771